Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Sleep and Cognitive Function in Multiple Sclerosis.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Novel MS Drugs Advance
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Association between beta-interferon exposure and hospital events in multiple sclerosis.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Optical Coherence Tomography in Multiple Sclerosis.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Development of a Bilingual MS-Specific Health Classification System: The Preference-Based Multiple Sclerosis Index.
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
Effect of smoking on multiple sclerosis: a meta-analysis.
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Extended interval dosing of natalizumab in multiple sclerosis.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Pages